FIELD: immunology.
SUBSTANCE: fused peptide capable of binding to both CD137 and glypican-3 (GPC3), nucleic acid molecule, host cell, methods for producing fused polypeptide are proposed. Besides, use of fused polypeptide, method for simultaneous activation of descending signal paths, method for simultaneous co-stimulation of T-cells and impact on GPC3-positive tumor cells are considered. Method for directing cluster formation and CD137 activation on T-cells relatively to GPC3-positive tumor cells, method for treating cancer and pharmaceutical composition are also proposed.
EFFECT: present invention can be further used in the therapy of cancer related to CD137 and GPC3.
34 cl, 26 dwg, 19 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
